NasdaqGM - Nasdaq Real Time Price USD

Merus N.V. (MRUS)

52.90

-0.81

(-1.51%)

At close: June 7 at 4:00 PM EDT

52.90

0.00

(0.00%)

After hours: June 7 at 6:18 PM EDT

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. “These data continue to support our view th

GlobeNewswire 4 days ago

MRUS
-1.51%
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4,

GlobeNewswire 5 days ago

MRUS
-1.51%
Merus Announces Pricing of Upsized Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purch

GlobeNewswire 9 days ago

MRUS
-1.51%
These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat

The latest analyst coverage could presage a bad day for Merus N.V. ( NASDAQ:MRUS ), with the analysts making...

Simply Wall St. 9 days ago

MRUS
-1.51%
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET. The webcast of the presentation will be contemporaneous

GlobeNewswire 9 days ago

MRUS
-1.51%
Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underw

GlobeNewswire 10 days ago

MRUS
-1.51%
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a March 6, 2024 data cutoff from the ongoing phase 1/2 trial of the bispecific antibody

GlobeNewswire 11 days ago

MRUS
-1.51%
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.

Zacks 11 days ago

MRUS
-1.51%
ARQT

MRNS
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

Merus stock catapulted to a record high Friday after its experimental regimen for head-and-neck cancer beat expectations in a key study.

Investor's Business Daily 14 days ago

MRUS
-1.51%
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?

Thursday, Merus N.V. (NASDAQ:MRUS) announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting website. Keytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract presents interim clinical data from a cohort of 26 patients enrolled as of the abstract cutoff date, evaluating the combination in first-line (1L) recurrent/metastatic (r/m) head and neck squa

Benzinga 14 days ago

MRUS
-1.51%
Merus Clears Wall Street's Bar With Cancer Data

Merus appears to have cleared the bar set by Wall Street for its highly watched cancer-treatment candidate. The company posts an abstract for its head and neck cancer treatment on Thursday, boasting a 60% response rate and one complete response in a pool of 10 evaluable patients. William Blair analysts say in a research note that the early dataset is a clear encouraging sign on the potential treatment's efficacy.

Barrons.com 14 days ago

MRUS
-1.51%
Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities

Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities

PREMIUM
MT Newswires 14 days ago

MRUS
-1.51%
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.

Barrons.com 14 days ago

MRUS
-1.51%
IMCR

MRNA
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.

Pharmaceutical Technology 14 days ago

MRUS
-1.51%
GLDAF
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

- 60% response rate observed among 10 evaluable patients - Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed - Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific a

GlobeNewswire 15 days ago

MRUS
-1.51%
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation: June 3, 2024, 1:30-4:30 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®

GlobeNewswire 15 days ago

MRUS
-1.51%
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metast

GlobeNewswire 25 days ago

MRUS
-1.51%
Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Merus N.V. ( NASDAQ:MRUS ) shareholders are probably feeling a little disappointed, since its shares fell 7.9% to...

Simply Wall St. 27 days ago

MRUS
-1.51%
Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...

Simply Wall St. 28 days ago

MRUS
-1.51%
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRU

GlobeNewswire 30 days ago

MRUS
-1.51%

Performance Overview

Return	MRUS	S&P 500
YTD	+92.36%	+12.10%
1-Year	+132.02%	+24.82%
3-Year	+155.80%	+26.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merus N.V. (MRUS)

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

Merus Announces Pricing of Upsized Public Offering of Common Shares

These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Merus N.V. Announces Proposed Public Offering of Common Shares

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?

Merus Clears Wall Street's Bar With Cancer Data

Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Performance Overview